BPC-157 Dosage: What Research & Community Protocols Report

---

The short version

BPC-157 is a synthetic 15–amino-acid peptide (a "pentadecapeptide") derived from a protein found in human gastric juice. It has been studied in well over a hundred preclinical experiments for tendon, ligament, muscle, gastrointestinal, and neurological repair — but the evidence base is overwhelmingly in rodents. Because there is no approved product, there is no titration schedule, no maximum dose, and no maintenance dose in any regulatory sense. What circulates online are extrapolations from animal work and anecdote, which is exactly why they should be read critically rather than followed.

How it was dosed in research

In animal studies, BPC-157 doses are almost always expressed per kilogram of body weight — frequently in the microgram-per-kg to low milligram-per-kg range, given by injection or orally. Per-kilogram animal dosing does not convert cleanly to a human dose: differences in metabolism, surface area, and route make naive scaling unreliable and potentially unsafe. The 2025 first-in-human pilot took a different approach, administering single intravenous doses escalating up to 20 mg under clinical monitoring, and reported no serious adverse events at those doses. That is a safety signal in a controlled setting — not a recommended regimen.

What community protocols report

The figures shared in forums and clinic hand-outs are not validated, but documenting them helps readers recognize what they are looking at. Reported subcutaneous protocols cluster around the following pattern. These are descriptive, not prescriptive.

Reported use	Reported amount	Frequency	Duration	Route
Localized tissue repair	250–500 mcg	1–2× daily	4–6 weeks	SubQ near the site
"Aggressive" repair	500–750 mcg	2× daily	4–8 weeks	SubQ near the site
GI / gut	250–500 mcg	2× daily	4–8 weeks	SubQ (abdominal) or oral
Systemic / general	250 mcg	1× daily	4 wks on / 2 off	SubQ, rotating sites

Note the consistent themes: small microgram amounts, once or twice daily, in multi-week blocks. None of this has been validated in a human efficacy trial, and the "near the injury" rationale is itself extrapolated from animal models rather than demonstrated in people.

Reconstitution basics

BPC-157 sold as a "research" product is a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before any amount can be drawn into a syringe. The arithmetic — vial strength ÷ diluent volume = concentration, then desired amount ÷ concentration = volume to draw — is where mistakes most often happen, and a microgram-scale error is easy to make. If you are working through that math conceptually, our tools handle it precisely:

→ Reconstitution Calculator — converts vial strength + BAC water volume into an exact syringe draw, with a visual syringe (BPC-157 is pre-loaded with default values).
→ Mixing & Administration Guide — sterile technique, storage, and handling.

A calculator can do the arithmetic, but it cannot make an unapproved compound safe, sterile, or correctly identified. Reconstituted solution is typically refrigerated at 2–8 °C and discarded within about 28 days; powder is kept frozen. Those handling notes reduce spoilage — they do not address the deeper unknowns of an unregulated product.

Where BPC-157 stands legally

This matters for dosing because it explains why no official schedule exists. The FDA placed BPC-157 on its 503A Category 2 list (substances raising significant safety concerns, not eligible for compounding) in 2023. On April 15, 2026, after the nominations were withdrawn, BPC-157 was among twelve peptides removed from Category 2 — but removal does not confer Category 1 status or approval. It is now scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on July 23, 2026, where the use under evaluation is ulcerative colitis. Until that process concludes, BPC-157 sits outside the approved-medicine framework. See our Regulatory Status Tracker for the live picture.

Frequently asked questions

Why are doses given in micrograms, not milligrams?

Community injection protocols use microgram amounts (250 mcg = 0.25 mg). The 2025 human pilot used milligram IV doses in a clinical setting. The mismatch underscores that "a dose" depends entirely on route and context — and that none of it is standardized.

Is oral BPC-157 dosed differently?

Some GI-focused research and compounded capsules use the oral route, on the theory that a gastric-derived peptide may act locally in the gut. Oral bioavailability is believed to be lower than injection, and head-to-head human data are lacking, so reported oral amounts are even more speculative.

What is the "safe maximum"?

There isn't one in any approved sense. The 2025 pilot found no serious adverse events at single IV doses up to 20 mg, but a short safety study cannot define a long-term safe ceiling. Theoretical concerns — for example around angiogenesis in people with active cancer — remain unresolved.

---

Sources

1. First-in-human pilot of intravenous BPC-157 safety at escalating doses up to 20 mg (2025). PMID 39284103.
2. Systematic review of BPC-157 and tendon healing across preclinical studies (2024). PMID 38221944.
3. U.S. FDA — 503A bulk drug substances list update and Category 2 removals, April 15, 2026; PCAC meeting notice for July 23–24, 2026.

Medical disclaimer: Education only, not medical advice. BPC-157 is investigational and not approved for human use. Dosing figures reflect research and community reports, not a recommendation. Do not self-administer; consult a licensed clinician. The only verified-safe path to treatment is an FDA-approved medicine under a clinician's supervision.